share_log

Processa Pharmaceuticals | 8-K: Current report

Processa Pharmaceuticals | 8-K: Current report

Processa Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  07/02 12:58

Moomoo AI 已提取核心信息

On June 28, 2024, Processa Pharmaceuticals held its 2024 Annual Meeting of Shareholders, with a quorum achieved through the presence of shareholders representing a majority of the voting power. During the meeting, shareholders voted on several key proposals. All six director nominees were elected to serve until the next annual meeting. Additionally, an amendment to increase the number of shares available under the Processa Pharmaceuticals 2019 Omnibus Incentive Plan by 500,000 was approved. BD & Company, Inc. was ratified as the independent registered public accounting firm for the year 2024. Furthermore, the compensation of the company's named executive officers received approval through an advisory vote. The results of these votes were filed with the SEC in a Form 8-K report, signed by James Stanker on July 1, 2024.
On June 28, 2024, Processa Pharmaceuticals held its 2024 Annual Meeting of Shareholders, with a quorum achieved through the presence of shareholders representing a majority of the voting power. During the meeting, shareholders voted on several key proposals. All six director nominees were elected to serve until the next annual meeting. Additionally, an amendment to increase the number of shares available under the Processa Pharmaceuticals 2019 Omnibus Incentive Plan by 500,000 was approved. BD & Company, Inc. was ratified as the independent registered public accounting firm for the year 2024. Furthermore, the compensation of the company's named executive officers received approval through an advisory vote. The results of these votes were filed with the SEC in a Form 8-K report, signed by James Stanker on July 1, 2024.
2024年6月28日，processa pharmaceuticals举行了2024年股东大会，以出席代表大多数投票权的股东为法定人数，取得了法定人数。在会议期间，股东对几个重要的提案进行了表决。所有六位董事候选人当选，任期至下次股东大会。此外，已批准一项修正案，将processa pharmaceuticals 2019年全员股权激励计划中可用股数增加50万股。BD & Company, Inc.被署名为2024年独立注册公共会计师事务所。此外，对公司的认可投票通过了对本公司命名高管的薪酬。这些表决的结果已在形式为8-K的报告中提交给SEC，由詹姆斯·斯坦克于2024年7月1日签署。
2024年6月28日，processa pharmaceuticals举行了2024年股东大会，以出席代表大多数投票权的股东为法定人数，取得了法定人数。在会议期间，股东对几个重要的提案进行了表决。所有六位董事候选人当选，任期至下次股东大会。此外，已批准一项修正案，将processa pharmaceuticals 2019年全员股权激励计划中可用股数增加50万股。BD & Company, Inc.被署名为2024年独立注册公共会计师事务所。此外，对公司的认可投票通过了对本公司命名高管的薪酬。这些表决的结果已在形式为8-K的报告中提交给SEC，由詹姆斯·斯坦克于2024年7月1日签署。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间